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Abstract
Objective: To provide cross-sectional height and head circumference (HC) references for healthy Dutch children with Down
syndrome (DS), while considering the influence of concomitant disorders on their growth, and to compare growth between
children with DS and children from the general population.
Study design: Longitudinal growth and medical data were retrospectively collected from medical records in 25 of the 30
regional hospital-based outpatient clinics for children with DS in the Netherlands. Children with Trisomy 21 karyotype of
Dutch descent born after 1982 were included. The LMS method was applied to fit growth references.
Results: We enrolled 1,596 children, and collected 10,558 measurements for height and 1,778 for HC. Children with DS
without concomitant disorders (otherwise healthy children) and those suffering only from mild congenital heart defects
showed similar growth patterns. The established growth charts, based on all measurements of these two groups,
demonstrate the three age periods when height differences between children with and without DS increase: during
pregnancy, during the first three years of life, and during puberty. This growth pattern results in a mean final height of
163.4 cm in boys and 151.8 cm in girls (22.9 standard deviation (SD) and 23.0 SD on general Dutch charts, respectively).
Mean HC (0 to 15 months) was 2 SD less than in the general Dutch population. The charts are available at www.tno.nl/
growth.
Conclusions: Height and HC references showed that growth retardation in otherwise healthy children with DS meanly
occurs in three critical periods of growth, resulting in shorter final stature and smaller HC than the general Dutch population
shows. With these references, health care professionals can optimize their preventive care: monitoring growth of individual
children with DS optimal, so that growth retarding comorbidities can be identified early, and focusing on the critical age
periods to establish ways to optimize growth.
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Introduction
Appropriate, up-to-date growth charts are necessary for
evaluation of physical growth and provision of optimal health
care. The World Health Organization has produced a global
standard chart describing how children, under optimal conditions,
grow worldwide. [1] This is based on the idea that all humans are
more or less equal. Health care workers, on the other hand, often
wish to use growth charts of a well defined reference group closely
related to the subpopulation they serve, since these charts provide
a more accurate evaluation for an individual child. [2] Growth
charts are available for various ethnic groups at specific moments
in time. [3,4] Specific growth references have also been developed
for children with various disorders known to interfere with growth,
such as Turner and Down syndrome (DS). [5–9] Since growth
assessment depends on the growth pattern characteristic for these
conditions, disorder specific charts are desirable. Growth refer-
ences for American children with DS have been constructed
making it possible to accurately identify concomitant disorders
known to influence growth. [6] Growth charts for Dutch children
with DS were first published in 1996: they are shorter than
children in the general Dutch population, but taller than their US
peers with DS. [8]
In order to take the secular trend into account, growth
references for height and head circumference (HC) need to be
updated regularly. [3] Children with DS are at high risk of many
disorders known to influence growth. Such disorders are generally
regarded as exclusion criteria in growth studies: all children
diagnosed with growth disorders or on medication known to
interfere with growth are usually excluded. [3] However, in studies
on growth in children with DS such exclusion criteria are usually
not applied. [5–8,10] Only two recent growth studies in children
with DS (in Japan and in the UK and Ireland) excluded children
with various diagnoses known to affect growth. [11,12] In
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funders had no role in study design, data collection and analysis, decision to publish, or prepar tion of the maunscript Research (NWO). The  aaddition, no previous studies have investigated in which particular
age periods height growth in otherwise healthy children with DS is
relatively most delayed, by comparing their growth with that of
healthy controls from the general population.
Therefore, the aim of the present study is to provide updated
height and new HC growth references by a large nationwide
sample, reflecting healthy growth in Dutch children with DS, and
to compare their growth pattern with data from a recent
nationwide study among children from the general Dutch
population with focus on periods during which relative height
differences increases. We think it is essential to establish new
growth references for children with DS in the Netherlands,
whereby a strict selection on their health status will be applied.
Only with such references health care professionals can monitor
growth of individual children with DS optimally, and can identify
growth retarding comorbidities at an early stage.
Methods
Data source
To collect representative nationwide data, all specialized
regional pediatric outpatient clinics for children with DS in the
Netherlands were approached (n=30). These hospital-based
clinics provide standard medical care for children with DS,
according to the guideline of the Pediatric Association of the
Netherlands. [13] All children with DS, who live in the service
area of these clinics, are eligible to participate in this standard care
by specialized pediatricians that includes screening for congenital
cardiac defects, thyroid dysfunction, celiac disease, hearing and
visual disorders as well as motor development and growth
monitoring. Youth health care physicians working in special
education and looking after older children with DS were also
approached. Names of all participating clinics, pediatricians and
youth health care physicians are mentioned in the acknowledge-
ment.
At the clinics all data were retrospectively collected from
medical records, between July 2009 and February 2010, by the
first author, who is a trained physician. The de-identification was
also completed by the first author, using study numbers.
Additional data from the youth health care physicians caring for
older children with DS in special education were collected by
completing standard forms. All measurements were carried out
according to protocol. [14] Height was measured using a
recumbent length device or a stadiometer and HC by using a
measuring tape (fiberglass or other non-expanding material). Data
concerning medical conditions and treatment of each subject, and
specifically those conditions known to interfere with growth, were
gathered from medical records, as well as specific background
information. Children were considered to be of Dutch descent if
both parents were born in the Netherlands, as reported in the
medical records. If medical or background information was not
available, subjects were excluded.
Inclusion/exclusion
Children with Trisomy 21 karyotype were selected, and those
with DS caused by mozaı ¨cisme or translocation were excluded
(verified by karyotype). All children born after 1982 were included
(aged up to 26 years). We collected semi-longitudinal data on
growth over the previous 10 years, recording data from 2000
onwards. We selected only the first recorded observation per
interval: from an infant (age of 0 to 1 year old) one observation in
each month, from a toddler (age 1 to 3 years old) one observation
in each three months period, and one observation in each six
months in childhood and adolescence (age up to 26 years old).
Measurements of HC were selected only from full-term children
(born $37 weeks gestation) up to the age of 5 year. If gestational
age was not specifically mentioned, children were considered to be
born at term.
Health status
The children were categorized according to their health status
in 4 groups: healthy, with only mild CHD, with only severe CHD
or with other (multiple) concomitant disorders. Table 1 describes
the characteristics of the various health categories and details of
the criteria used for these categories.
Permission of an Ethical Committee or informed consent is not
obtained, as not required in the Netherlands for this type of study
or data collection, since the data were analyzed anonymously.
Statistical Analysis
Data cleansing was performed by excluding duplicate cases and
outliers. Duplicate cases have arisen when children were seen at
Table 1. Characteristics of the various health categories in the study population of children with Down syndrome.
Healthy
Children without concomitant disorders that could possibly interfere with growth
Children were negatively screened for CHD, celiac disease and hypothyroidism
For example: children with cataract were included and children with musculoskeletal disorders were excluded
Mild CHD
Children with CHD not needing surgical intervention or medication and without pulmonary vascular disease
For example: children with an atrial septal defect or patent foramen ovale without complaints
Severe CHD
Children with CHD needing surgical intervention, medication, or with pulmonary vascular disease
For example: children with an atrioventricular septal defect or Tetralogy of Fallot
Other disorders
Children with other disorders and treatments known to interfere with growth, and children with multiple concomitant disorders
For example: children positively screened for hypothyroidism or celiac disease, children with congenital gastrointestinal disorders, children on anti-epileptic
medication or corticosteroids (including inhalation medication)
Abbreviation: CHD – congenital heart defect.
doi:10.1371/journal.pone.0031079.t001
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birth and background information such as nationality, and
medical condition. Outliers were defined using height and HC
standardized by age and sex according to the reference charts of
the general Dutch population, calculated in standard deviation
scores (SDS). [3] Cutoff values .2o r,26 for height SDS and
HC SDS were used. If a child had one measurement outside the
cutoff values, all measurements of this child were excluded.
Moreover, the longitudinal growth pattern of each subject was
checked by plotting them and excluding values outlying the plot.
Data were analyzed separately for boys and girls.
The difference in mean height SDS and HC SDS between
healthy children withDS and children with DS and a mild or severe
CHD were tested by linear mixed-effects models. To correct for
possible differences in the prevalence rates of sex and mean age, we
adjusted these analyses by age and sex. Furthermore, growth
references for boys and girls with DS were fitted for body height by
age (range 0 to 21 years) and HC by age (range 0 to 15 months)
using the LMS method. Growth references were fitted in R Version
2.9.0 using Generalized Additive Models for Location Scale and
Shape (GAMLSS). [15] The LMS method summarizes the
distribution by three age-dependent smooth curves representing
skewness (L curve), median (M curve) and coefficient of variation (S
curve). [16] The LMS method is based on the principle that after a
transformation the data have to follow a standard normal
distribution. The following transformations of age were tested to
expand the ages where growth velocity is high and compress age
where growth velocity is low: the age transformation proposed by
Cole, a square root transformation, a log transformation and a cube
root transformation. [17] Worm plots were used as a diagnostic tool
to visualize the fit to the data. [18] These plots check the residuals
for different age levels and indentify locations at which the fit can be
improved. We fitted charts with lines of the 22.5, 22.0,21.0, 0,
1.0, 2.0 and 2.5 SD (corresponding with 0.6, 2.3, 15.9, 50, 84.1,
97.7 and 99.4 percentile). The choice of these SD-lines is in
agreement with the latest reference charts for the general Dutch
population. We did not fit growth charts for the health category
‘other disorders’, because of the wide variety of data and medical
conditions of the children in this category. Also, growth charts for
subgroups in this category – like children with hypothyroidism or
celiac disease – were not fitted, because of the small number of
children included in our study.
In addition to the reference charts for height, formulas for Target
Height (TH) for children with DS were calculated. [19] The TH
was calculated by the method of Hermanussen and Cole, which
takesintoaccounttwocorrelations(assortativematingr(P,P)andthe
parent-offspring correlation r(P,O)). [20] For this calculation, the
data from three nationwide sources have been applied. The
correlations were obtained from the latest growth study in the
general Dutch population (2009) and were r(P,P)=0.19 and
r(P,O)=0.58. [21] The calculation for the paternal and maternal
height SD was based on the results from the previous national
growth study (1997); final height of children measured in this study
corresponds with final height of this generation of parents. [3] For
the calculation of the TH SDS the mean and SD of final height of
the children with DS observed in this study were used.
The established growth references for height and HC were
compared with the most recent reference charts for the general
Dutch population, by calculating SDS. [21]
Results
Pediatricians working in 25 hospital-based clinics (83% of all
Dutch DS clinics) and 14 youth health care physicians caring for
older children with DS in special education agreed to participate
in this study. After exclusion of 7 children with a growth pattern
outside the cut-off values, a total of 1,843 children with Trisomy
21 were indentified. Of these, 1,596 are of Dutch origin: 891 boys
(55.8%) and 705 girls (44.2%). The sample provided 10,558
measurements for height and 1,778 for HC in the age range 0 to 5
years and born at term (418 HC measurements from children born
pre-term in this age range were excluded). Of all height
measurements, 98% were derived from the DS clinics and 2%
from the youth health care physicians in special education. The
HC measurements were only derived from the DS clinics. Table 2
provides total number of subjects and measurements of height and
HC, split according to sex and to various health categories. In our
sample, 26.6% was categorized as healthy, 15.0% had only a mild
CHD and 16.9% only a severe CHD. The remaining group,
41.5%, was categorized as having various other disorders; most of
them (over 60%) had multiple concomitant disorders.
Growth of children with DS within various health
categories
Growth of healthy children with DS and those who suffer from
mild CHD showed no difference in mean height SDS (p=0.832)
and HC SDS (p=0.790). Both girls and boys with DS and severe
CHD had significant lower mean height SDS and HC SDS
compared to healthy children with DS or children with DS with
mild CHD (both p-values,0.001). Mean height is observed to be
0.4 SD lower. This growth retardation arises in the first year of life;
during childhood no further deflection neither catch-up growth
was observed.
Growth references
Data for growth references of height and HC were derived by
combining the groups of healthy children with DS and children
with DS and mild CHD (664 children for height, and 223 for HC
(see Table 2). The number of measurements of these selected
groups, arranged by age en sex, are shown in Table 3. By fitting
the growth references for height, the cube root transformation of
age showed the best fit and was selected. Table 4 summarizes
mean height and SD, arranged by age and sex. Mean birth length
was 48.9 cm in boys and 48.4 cm in girls with DS. Mean final
height was 163.4 cm in boys and 151.8 cm in girls. These new
reference charts are available at www.tno.nl/growthhttp://www.
tno.nl/growth.
Table 2. Number of subjects and measurements for height
and head circumference of 1,596 Dutch subjects with Trisomy
21, specified by the health categories.
Subjects Measurements
Height HC
1 Height HC
Health
category Boys Girls Boys Girls Boys Girls Boys Girls
Healthy 257 167 71 57 1,378 938 202 139
Mild CHD 130 110 49 46 751 661 169 147
Severe CHD 114 155 38 50 738 997 134 187
Other disorders 390 273 140 88 2,970 2,125 443 357
Total 891 705 298 241 5,837 4,721 948 830
Abbreviations: HC – head circumference, CHD – congenital heart defect.
1Only children born full-term up to the age of 5 years were included.
doi:10.1371/journal.pone.0031079.t002
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15 months. We did not have enough measurements to construct
growth references after the age of 15 months. By fitting HC
references for boys no transformation of age and for girls the age
transformation proposed by Cole was applied. [17] Table 5
summarizes the LMS-values, arranged by age and sex. At birth
mean HC was 33.8 cm in boys and 32.9 cm in girls with DS; at
the age of 15 months this was 45.0 cm and 43.7 cm respectively.
Target Height
The calculated formulas for TH of children with DS are:
TH boys DS cm ðÞ ~41:8z0:328| paternal height ðÞ z
0:359| maternal height ðÞ
Table 3. Frequencies of measurements for height used for
plotting the reference curves for Dutch children with Down
syndrome, arranged by age and sex.
Height
1
Age (years) Male Female Total
0 474 392 866
1 241 201 442
2 201 147 348
3 178 129 307
4 151 101 252
5 132 96 228
6 117 86 203
78 3 8 9 1 7 2
8 105 66 171
98 6 4 9 1 3 5
10 72 52 124
11 62 46 108
12 68 37 105
13 52 29 81
14 36 28 64
15 31 12 43
16 20 14 34
17 8 6 14
$18 12 19 31
Total 2129 1599 3728
Head circumference
2
Age (years) Male Female Total
0 244 199 443
16 9 5 0 1 1 9
22 2 1 8 4 0
31 9 1 0 2 9
41 7 9 2 6
Total 371 286 657
1Height measurements of the children categorized as healthy or with only mild
CHD (n=664).
2Head circumference of the children categorized as healthy or with only mild
CHD, born at term (n=223).
doi:10.1371/journal.pone.0031079.t003
Table 4. Mean height (cm) and standard deviation (SD) of the
new references for length/height of Dutch children with
Down syndrome, arranged by age and sex.
Boys Girls
Age (weeks) Mean SD* Mean SD*
0 48.9 2.5 48.4 2.1
2 50.4 2.6 49.8 2.2
4 51.9 2.6 51.3 2.2
6 53.4 2.6 52.6 2.2
8 54.8 2.6 54.0 2.2
10 56.2 2.6 55.3 2.2
12 57.5 2.6 56.5 2.3
16 60.0 2.6 58.7 2.3
20 62.2 2.6 60.7 2.3
24 64.1 2.7 62.6 2.4
28 65.8 2.7 64.2 2.4
32 67.3 2.7 65.7 2.4
36 68.6 2.7 67.0 2.5
40 69.8 2.7 68.2 2.5
44 70.9 2.8 69.3 2.5
48 71.9 2.8 70.3 2.6
52 73.0 2.8 71.3 2.6
Age (years)
1.5 78.3 3.0 76.4 2.8
2.0 82.6 3.1 80.8 3.0
2.5 86.4 3.3 84.6 3.2
3.0 89.8 3.5 88.1 3.5
3.5 93.1 3.7 91.6 3.7
4.0 96.4 3.9 95.2 3.9
4.5 99.7 4.0 98.6 4.1
5.0 102.9 4.2 101.7 4.3
6.0 109.0 4.5 107.2 4.6
7.0 114.7 4.8 113.0 4.9
8.0 119.9 5.0 118.7 5.2
9.0 125.2 5.3 124.0 5.5
10.0 130.8 5.5 129.3 5.8
11.0 136.8 5.7 134.4 6.1
12.0 142.9 5.8 139.1 6.3
13.0 148.7 5.9 142.9 6.5
14.0 153.5 6.0 145.9 6.6
15.0 157.2 6.1 147.9 6.8
16.0 159.8 6.2 149.4 6.9
17.0 161.8 6.2 150.5 7.0
18.0 163.0 6.2 151.2 7.1
19.0 163.4 6.2 151.6 7.2
20.0 163.4 6.2 151.8 7.3
21.0 163.4 6.2 151.8 7.3
*Individual height SDS can be calculated by: SDS=(height (cm)2mean height
(cm))/SD (cm).
Abbreviations: SD – standard deviation, SDS – standard deviation score.
doi:10.1371/journal.pone.0031079.t004
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TH girls DS cm ðÞ ~8:64z0:387| paternal height ðÞ z
0:422| maternal height ðÞ
TH SDS girls DS SD ðÞ ~ TH girl DS{151:8 ðÞ =7:3:
Comparison to the general Dutch population
In comparison with the currently used reference charts for the
general Dutch population, a markedly shorter stature was found in
children with DS. [21] Mean height revealed a deflection in the
first 3 years of life from 21.1 SD at birth to 22.2 SD at 3 years,
for boys as well as girls. During the age interval of 3 to 12 years
average growth remained stable at 22.2 SD, and deflected again
during puberty to a final height at 22.9 SD (20.4 cm shorter) for
boys and 23.0 SD (18.9 cm shorter) for girls (Figure 1). [21] For
HC, between birth and 15 months, mean values for boys and girls
with DS are on average 1.8 SD lower (range 21.3 to 22.0)
compared to the general Dutch population. [3]
Discussion
This study yields new charts of healthy growth of children with
DS. Growth patterns were analyzed in 1,596 Dutch children with
DS, with 10,558 height measurements and 1,778 HC measure-
ments. All children were selected nationwide from pediatric
hospital-based outpatient clinics specialized in the standard care of
children with DS. Selection based on health complaints or
influenced by financial restrictions was avoided, since all children
with DS in the Netherlands were invited to avail of this care
without financial barriers, as encouraged by the Dutch Down
Syndrome Foundation (largest Dutch parent supporting organi-
zation). The result is a nationwide representative sample.
Our new reference charts for Dutch children with DS are
unique. No previous studies on growth in DS made such a
stringent selection of subjects with respect to their health. All
children have received high quality medical care according to the
guideline of the Pediatric Association of the Netherlands and
underwent standard screening at regular intervals, provided by the
regional hospital-based outpatient clinics for children with DS.
[13] This screening programme provided confidence that children
categorized as healthy in fact have no undiagnosed concomitant
disorders, such as hypothyroidism, mild CHD and celiac disease.
To illustrate the stringent selection: children with positive
screening results for hypothyroidism and celiac disease were
excluded (even though appropriate treatment was started early),
because there is no evidence that growth could not be affected
already.
The children with severe CHD showed growth retardation
during the first year of life. After this period they had growth
velocities similar to the healthy children with DS. In the
Netherlands the surgical correction of significant CHD takes
place preferably at the age of 2–4 months. [22] This early
treatment may result in normal growth after the age of 1 year
without further deflection. Cronk et al.also described growth
retardation caused by CHD in children with DS. [6] However,
they were unable to evaluate the effects of different types of cardiac
lesions (those which healed spontaneously or those treated by
corrective surgery) on growth. The present study provided
appropriate data to make this distinction.
When comparing mean final heights of children with DS with
other countries, we should take into account the different inclusion
Table 5. New head circumference (cm) references for 0–15
months in Dutch children with Down syndrome: values of L
(skewness), M (median), and S (coefficient of variation)*,
categorized by age and sex.
Boys Girls
Age (weeks) L M S* L M S*
0 2.96 33.8 .0349 1 32.9 .0267
2 2.65 34.6 .0343 1 33.8 .0272
4 2.34 35.3 .0336 1 34.7 .0277
6 2.03 36.1 .0330 1 35.5 .0280
8 1.72 36.8 .0324 1 36.4 .0281
10 1.42 37.5 .0319 1 37.1 .0279
12 1.12 38.2 .0313 1 37.8 .0276
16 0.54 39.4 .0302 1 38.8 .0270
20 20.01 40.4 .0292 1 39.7 .0265
24 20.52 41.2 .0283 1 40.4 .0261
28 20.99 42.0 .0274 1 41.0 .0259
32 21.41 42.6 .0266 1 41.5 .0257
36 21.80 43.1 .0258 1 42.0 .0255
40 22.14 43.5 .0250 1 42.3 .0254
44 22.45 43.9 .0243 1 42.7 .0252
48 22.72 44.2 .0237 1 42.9 .0251
52 22.97 44.4 .0231 1 43.2 .0249
56 23.19 44.6 .0225 1 43.3 .0248
60 23.40 44.8 .0221 1 43.5 .0247
65
a 23.64 45.0 .0216 1 43.7 .0245
aCorresponding with 15 months.
*Individual head circumference SDS can be calculated by: SDS={(height (cm)/
M)
L21}/L*S, L?0 (if L=0: SDS=ln(height (cm)/M)/S).
doi:10.1371/journal.pone.0031079.t005
Figure 1. Mean height (SDS) of the Dutch children with Down
syndrome compared to the general population. Comparison is
made to the mean height of the national Dutch growth study (2009),
calculated in standard deviation score (SDS).
doi:10.1371/journal.pone.0031079.g001
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reasonable to conclude that Dutch children with DS are relatively
tall among children with DS. Growth charts are available for
West-European children with DS in Sweden, the UK and Ireland,
and Northeastern France. [5,12,23]
Our study is the first to propose formulas to estimate the
expected final height in children with DS. The TH formulas were
derived under the assumption that the correlation between mid
parental height SD and child height SD in Dutch children with DS
is identical to the general Dutch population. Further research is
needed to investigate whether this assumption is justified.
We compare HC in our population with values published by
others. Reference charts for HC are also available for children
with DS from Sweden, Northeastern France, Sicily, UK and
Ireland, the USA, Egypt and Saudi Arabia, suitable for use in
these countries. [5,10,12,23–26] Benefits of our study are the
LMS-values presented, whereby for each individual the deviation
exactly can be calculated. Comparing HC showed the Swedish
children with DS have an average HC of 33 cm at birth, similar to
our children with DS. [5] This mean values at birth corresponds
with 20.5 SD on the reference charts for the general Swedish
population, however with 21.5 SD for the general Dutch
population. At 15 months mean HC is also identical in Swedish
and Dutch children with DS. Since the other studies do not
present enough details of their observations, we were unable to
make further comparisons.
What are the main differences in growth pattern between DS
and the general population? Mean birth length in DS is 1 SD
lower than in the general population, indicating that children with
DS already show retarded growth during pregnancy. Also, during
the first three years of life they grow slower compared to the
general population; the gap stays relatively constant during the age
interval 3–12 years. After the age of 12 year a further deflection in
growth is observed. This pattern is observed to be the same in boys
and girls with DS. The mentioned three periods are already
described by Karlberg et al. in the infant-childhood-puberty (ICP)
model, which described during infancy (from birth up to about 3
years of age) and during puberty higher growth velocity than
during childhood. [27] So, the children with DS show growth
retardation just during the critical periods of growth when the
highest growth velocity occurs. This finding indicate the age
periods in which further health benefit may be obtained. Health
care professionals should focus on these critical periods when
providing preventive care to children with DS with the aim to
establish ways to optimize growth during these specific periods.
Either the observed growth retardation may be due to their genetic
makeup or it may be caused by physical problems they encounter,
such as feeding problems. In puberty an early or short growth
spurt also limits final growth. Further research is needed to explain
our observations and to provide physiological clarification on the
nature of this growth retardation. All in all, these effects result in a
substantial difference in final height (boys: 20.4 cm; girls:
18.9 cm).
Body weight will be reported separately. Because of the current
increase in the proportion of children with obesity, it is not
desirable to reflect the present distribution of weight in this
population. Therefore, the increase in the proportion of children
with obesity and the need for normative charts for weight deserve
special attention. [21,28]
A limitation of our study is that the measurements of height and
HC were retrospectively collected. This methodology may lead to
more variation in the measurements compared to studies that used
prospectively collected data, as all general Dutch growth studies
did. We were however unable to detect such increased
measurement variability in the data. The S-curves (which model
the coefficient of variation) were quite similar in our growth charts
and the charts of the general Dutch population (established in
2009). So, we do not expect that the used methodology had an
impact on the variability in the growth charts. A benefit of the
applied methodology is the larger and timelier data set. Similar
methods were used in other growth studies in children with DS.
[5,12,23]
The longitudinal data resulted in a varied number of
measurements per child. To determine the possible influence of
this variation, the statistical analyses were repeated where data
points were weighted – whereby a weighting factor was calculated
as the inverse of the number of measurements per child – in order
to prevent over-representing children with a large number of
measurements. This solution was almost the same as the
unweighted analysis; differences in mean height were smaller
than 0.1 SD.
For the interpretation of individual growth curves plotted on a
reference chart, criteria are needed to define abnormal growth. No
specific criteria for the charts for children with DS have been
proposed. The utility of the referral criteria for the general Dutch
population as presented in the guideline ‘Detection and referral
criteria in short stature’ has not been tested for growth in children
with DS. Further research is necessary to see whether such referral
criteria are equally suitable for children with DS. [29,30] For the
moment, we tentatively suggest to use the criteria for the general
population (which are all framed in SDS) for children with DS.
Implications
The availability of appropriate up-to-date growth charts, that
reflect healthy growth of height and HC in Dutch children with
DS, will potentially improve the medical care they receive. Using
Table 6. Growth studies presenting mean final height (cm) of children with Down syndrome, with the applied inclusion and
exclusion criteria, by country of origin.
Inclusion Exclusion criteria Boys Girls
The Netherlands This study T21 All concomitant disorders known to interfere with growth; separate analyses of mild and severe CHD 163.4 151.8
Sweden [5] 2002 DS Treatment with growth hormone 161.5 147.5
UK, Ireland [12] 2002 DS Coexistent major pathology such as severe CHD or preterm birth 157 146
Japan [11] 2003 T21 Complications that might affect natural growth 153.2 141.9
France [23] 1999 T21 Severe CHD 154 140
USA [6] 1988 T21 Separate analyses of moderate and severe CHD (if information is available) 153 146
Abbreviations: T21 – Trisomy 21, DS – Down syndrome (including DS caused by Trisomy 21, mozaı ¨cisme or translocation), CHD – congenital heart defect.
doi:10.1371/journal.pone.0031079.t006
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more accurately. For example, limited growth of height may be a
symptom of hypothyroidism and a relative large HC may be
caused by hydrocephalus. The charts were based on a large
sample that is stringently selected on the basis of their health
status, and therefore we will encourage research to investigate the
suitability of these charts for international application.
In children with DS with severe CHD growth is decelerated
during the first year of life, in comparison to reference growth in
the healthy infants with DS. During childhood no catch-up growth
is noticed in these children with DS and severe CHD, neither does
their growth decline further. Future research should focus on the
exact qualities of the observed deflections in growth of otherwise
healthy children with DS: is their growth spurt restricted with a
lower velocity or do other phenomena play a role. Lack of
significant catch up growth in children with DS and severe CHD
could be the result of similar failure to spurt. We can only
hypothesis on the full nature of growth retardation in otherwise
healthy children with DS: as their growth is primarily restricted by
Trisomy 21 the mechanism is unknown. Is it primarily metabolic,
hormonal or chondrocyte dysfunction? Or could it be explained
by further advanced genome-wide analysis?
Conclusions
Growth patterns in otherwise healthy Dutch children with DS
were established based on data from a large nationwide
population. Growth in healthy children with DS differ from
children with DS and severe CHD (0.4 SD). The established
growth charts demonstrate the three age periods when height
differences between children with and without DS increase: during
pregnancy, during the first three years of life, and during puberty.
This growth pattern results in a mean final height of 163.4 cm in
healthy boys with DS and 151.8 in girls (a difference of 3 SD in
comparison to the general population), and mean HC at birth of
33 cm and 44 cm at the age of 15 months (almost 2 SD less than
in the general Dutch population). All in all, with these new growth
charts, that reflect healthy growth in children with DS, health care
professionals can monitor growth of individual children with DS
optimal. In this way, early identification of growth retarding
comorbidities will be enabled and ultimately the health of children
with DS will be improved.
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